Two cancer-combating medicines show potential for protecting U.S. troops and civilians from biological weapon attacks from pathogens like monkeypox.
Just this week, monkeypox was involved in some of the eight cases of possible contact with dangerous biological agents at the U.S. Army Medical Research Institute of Infectious Diseases at Fort Detrick, Md. USAMRIID said last week there were 14 accidents in total involving personnel in full-body protective suits in 2012.
Part of the Department of Defense, the Defense Threat Reduction Agency counters weapons of mass destruction from chemical, biological and radiological through to nuclear and high yield explosive threats. The agency is funding St Louis University’s Mark Buller, who will look at cancer-fighting drugs Gleevec and Tasigna for preventing and treating monkeypox exposure.